Dr Reddys Laboratories (RDY) Non-Current Debt (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Non-Current Debt for 10 consecutive years, with $130.0 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Debt rose 41.3% year-over-year to $130.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $130.0 million (up 41.3% YoY) and the FY2026 annual result came in at $130.0 million, up 41.3% from the prior year.
• Non-Current Debt climbed to $130.0 million in Q1 2026 per RDY's latest filing, from $92.0 million in the prior quarter.
• Over the last five years, Non-Current Debt for RDY reached as high as $130.0 million in Q1 2026 and fell as low as $16.0 million in Q1 2023.
• A 5-year average of $77.2 million and a median of $76.0 million in 2022 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2023 — Non-Current Debt plunged 78.95% — and 2024, when it soared 350.0%.
• Year by year, Non-Current Debt stood at $76.0 million in 2022, then tumbled by 78.95% to $16.0 million in 2023, then surged by 350.0% to $72.0 million in 2024, then advanced by 27.78% to $92.0 million in 2025, then soared by 41.3% to $130.0 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $130.0 million, $92.0 million, and $72.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.